The FDA on 30 April granted approval of GlaxoSmithKline's Breo Ellipta (fluticasone furoate/vilanterol) as a once-daily inhaled treatment for asthma in adults.
But the agency rejected the medicine for use in adolescents 12-17 years with the disease, declaring in a complete response...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?